New hemophilia drug switch tested for safety
NCT ID NCT06145373
Summary
This study is checking if it's safe for people with severe hemophilia A to switch from their current preventive treatment (emicizumab) to a newer one (fitusiran). It will involve about 20 male participants aged 12 and older who are already on emicizumab. Researchers will closely monitor for side effects and how well the new treatment controls bleeding over 18 months.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA A are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Hospital Los Angeles- Site Number : 8400005
RECRUITINGLos Angeles, California, 90027, United States
-
Investigational Site Number : 1580001
RECRUITINGTaipei, Podlaskie, 10041, Taiwan
Conditions
Explore the condition pages connected to this study.